Minoxidil was not developed for hair loss. It was synthesised in the 1960s as an oral antihypertensive vasodilator and marketed under the name Loniten for the treatment of severe hypertension. During clinical use, physicians and patients noticed an unexpected side effect: hypertrichosis, the growth of unwanted hair across the body. The observation was consistent enough to prompt investigation into whether a topical formulation could direct the effect to the scalp.

Topical minoxidil solution at 2% concentration received regulatory approval in the US for male androgenetic alopecia in 1988, followed later by a 5% formulation and by approval for use in women. A propylene glycol-free 5% foam formulation was subsequently developed to improve tolerability. More recently, oral low-dose minoxidil has gained significant clinical traction as an alternative route of administration, particularly for people who find topical application impractical or who experience scalp irritation from the vehicle ingredients.

Minoxidil itself is a prodrug. After topical application to the scalp, it is converted to its active form, minoxidil sulfate, by sulfotransferase enzymes present in the outer root sheath of the hair follicle, primarily the enzyme SULT1A1. This conversion step is significant: SULT1A1 activity varies considerably between individuals, and this variability is thought to be a major reason why some people respond strongly to minoxidil while others see little effect. People sometimes described as "non-responders" may simply have lower scalp sulfotransferase activity.

Minoxidil sulfate's best-characterised molecular action is opening ATP-sensitive potassium channels (KATP channels). This hyperpolarises cell membranes and causes vasodilation in the smooth muscle of blood vessel walls, explaining its original use as an antihypertensive. In the follicle microenvironment, the downstream effects include upregulation of vascular endothelial growth factor (VEGF) in dermal papilla cells, prolongation of the anagen (growth) phase, and an increase in follicle size. The precise signalling cascade linking channel opening to these follicular effects is not fully characterised, and research is ongoing into the additional molecular pathways involved.

Topical minoxidil is available in three main formulations, each with practical differences in application and tolerability.

Application technique matters more than is often recognised. Minoxidil should be applied directly to the dry scalp, not to the hair itself, using the dropper or nozzle to distribute it across the affected area. Hair does not need to be parted down to bare skin, but the active should reach the scalp surface rather than sitting on the hair shaft where it has no useful effect. Allowing the scalp to dry before contact with pillowcases or clothing reduces unintended transfer and potential for hypertrichosis at contact sites.

The scalp should be reasonably dry before application: applying to a wet scalp dilutes the active and may reduce absorption. Minoxidil does not need to be washed off after a fixed contact time; it is designed to remain on the scalp.

Low-dose oral minoxidil has gained considerable clinical traction in recent years as an alternative or adjunct to topical use. It is prescribed off-label in the UK specifically for hair loss, typically at doses between 0.25mg and 2.5mg daily, well below the antihypertensive doses (5 to 40mg) for which it was originally licensed. Women are typically started at lower doses (0.25 to 1mg) partly due to the higher risk of hypertrichosis at higher doses; men commonly use 1.25 to 2.5mg.

The practical advantage of oral over topical is consistency: systemic delivery means the active reaches follicles regardless of application technique, scalp type, or hair density. It also avoids the scalp irritation associated with the vehicle ingredients in topical solutions. Growing evidence suggests oral low-dose minoxidil is effective for both male and female pattern hair loss, and some clinical data suggests low-dose oral minoxidil may perform comparably to, and in some studies potentially better than, standard topical use.

Side effects at low doses are generally mild but include hypertrichosis (unwanted facial and body hair, particularly relevant for women), fluid retention, mild tachycardia, headache, and orthostatic hypotension. Serious cardiovascular effects are uncommon at these doses but a baseline cardiovascular assessment is appropriate before starting. This is a prescription decision requiring clinical oversight, not a self-managed one.

Topical minoxidil has one of the most extensive evidence bases of any hair loss treatment: decades of randomised controlled trials, well-characterised outcomes, and consistent findings across independent research groups. The broad picture from this body of work is that 5% solution produces superior outcomes to 2% in most head-to-head comparisons, and that both concentrations outperform placebo on objective measures including hair count, hair weight, and physician-rated assessments of coverage.

Response is variable. Approximately 40 to 60% of users in clinical trials show meaningful hair regrowth; the majority see stabilisation of further loss; a smaller proportion show no clear response. Vertex thinning generally responds better than frontal or temporal recession in most trial data, which reflects the follicle population differences at different scalp regions rather than a failure of mechanism. Women with diffuse crown thinning often respond well to both topical and oral formulations.

Timing matters for interpreting results. The minimum assessment period in most trials is six months; improvements continue to accrue through twelve months in some studies. Assessing response at six weeks or three months is too early and will underrepresent the eventual outcome. The article on how long before you see results covers this timeline in more detail.

A proportion of people starting minoxidil experience a noticeable increase in hair shedding in the first two to eight weeks. This is one of the most common reasons people stop using it prematurely, which is a significant problem because it typically precedes the period in which the treatment begins to show benefit.

The mechanism is understood: minoxidil promotes the transition of follicles from telogen (resting) into anagen (growth). Follicles sitting in late telogen are pushed forward into the next growth cycle, which requires shedding the existing telogen hair first before the new anagen hair can emerge. The result is a temporary increase in visible shedding that reflects cycle acceleration rather than worsening loss. The underlying follicles are not being lost; they are re-entering growth.

Minoxidil prolongs anagen and increases follicle size, but it does not address the underlying mechanism that is shortening anagen in the first place. In androgenetic alopecia, that mechanism is DHT-mediated miniaturisation. Minoxidil running alongside ongoing DHT-driven follicle damage is working against a process it cannot stop; the follicle benefits from a longer and more productive growth phase, but each successive cycle may still produce progressively finer hair if androgen suppression is not also in place.

Minoxidil also requires continuous use to maintain its effect. Discontinuation typically results in a return to pre-treatment hair density within three to six months as follicles revert to the cycling pattern they would have had without the drug. This is not a permanent loss beyond where the underlying AGA would have progressed to; it is a reversion, but it is an abrupt one. Anyone planning to stop should do so with that timeline in mind rather than abruptly.

It is not a cure and has no lasting structural effect on the follicle once discontinued. This is a meaningful distinction from treatments that address the androgen pathway, which may have more durable effects on the follicle's hormonal environment even after use patterns change.

Because minoxidil targets the vascular and growth-cycle dimensions of hair loss rather than the androgen pathway, it combines rationally with treatments that address different mechanisms. The most clinically established combination is minoxidil with finasteride or dutasteride: minoxidil provides the anagen-prolonging and vascular support while DHT suppression addresses the root hormonal driver. This combination is widely used in clinical practice and supported by the complementary rather than overlapping mechanisms. For how the two 5-AR inhibitors compare to each other directly, see finasteride vs dutasteride: a direct comparison.

This article is provided for educational purposes and does not constitute medical advice. Oral minoxidil is a prescription-only medication in the UK; consult a qualified healthcare professional before use. AmpleLab products are cosmetic formulations and are not intended to diagnose, treat, cure, or prevent any condition.

AmpleLab.